|
related topics |
{operation, international, foreign} |
{product, market, service} |
{property, intellectual, protect} |
{product, candidate, development} |
{regulation, government, change} |
{acquisition, growth, future} |
{cost, regulation, environmental} |
{stock, price, operating} |
{product, liability, claim} |
{tax, income, asset} |
{cost, contract, operation} |
{condition, economic, financial} |
{customer, product, revenue} |
{provision, law, control} |
{regulation, change, law} |
{stock, price, share} |
{operation, natural, condition} |
{cost, operation, labor} |
{debt, indebtedness, cash} |
{capital, credit, financial} |
|
A prolonged downturn in global economic conditions may materially adversely affect our business.
We may not realize anticipated benefits from global stimulus packages.
If our products fail to achieve and sustain sufficient market acceptance across their broad intended range of applications, we will not generate expected revenue.
Our products compete in markets that are subject to rapid technological change, and one or more of the technologies underlying our products could be made obsolete by new technology.
Our new technologies and product developments may not succeed.
If we are unable to make or complete future mergers, acquisitions or strategic alliances as a part of our growth strategy, or integrate recent or future mergers, acquisitions or strategic alliances, our business development may suffer.
Our business could be harmed if our collaborations fail to advance our product development.
If we are unable to recover significant development costs of one or more of our products or product lines, our business, results of operations and financial condition may suffer.
If we lose our strategic partners, our marketing efforts could be impaired.
Health care reform in the U.S. could adversely affect our revenue.
If general health care spending patterns decline, our ability to generate revenue may suffer.
Any reduction in the capital resources or government funding of our customers could reduce our sales and impede our ability to generate revenue.
Our operations are dependent upon a limited number of suppliers and contract manufacturers.
Increasing prices of metal raw materials could adversely affect the gross margins and profitability of our Bruker BioSpin subsidiary, and of our Bruker Energy Supercon Technologies business.
The demand for NMR, EPR, MRI and FTMS products may be adversely impacted by increases in the price of liquid helium.
Our manufacture and sale of products could lead to product liability claims for which we could have substantial liability.
Responding to claims relating to improper handling, storage or disposal of hazardous chemicals and radioactive and biological materials which we use could be time consuming and costly.
In addition to the risks applicable to our life science and materials analysis products, our CBRNE detection products are subject to a number of additional risks, including lengthy product development and contract negotiation periods and certain risks inherent in long-term government contracts.
We are subject to existing and potential additional regulation and government inquiry, which can impose burdens on our operations and narrow the markets for our products.
Our success depends on our ability to operate without infringing or misappropriating the proprietary rights of others.
If we are unable to effectively protect our intellectual property, third parties may use our technology, which would impair our ability to compete in our markets.
We may be involved in lawsuits to protect or enforce our patents that are brought by us which could be expensive and time consuming and, if determined adversely, could adversely affect our patent position.
We may not be able to maintain our sales and service staff to meet demand for our products and services.
We plan significant future growth, and there is a risk that we will not be able to manage this growth.
Armed hostilities could constrain our ability to conduct business internationally and could also disrupt our U.S. operations.
We derive a significant portion of our revenue from international sales and are subject to the risks of doing business in foreign countries.
We may lose money when we exchange foreign currency received from international sales into U.S. dollars.
Our reported financial results may be adversely affected by fluctuations in currency exchange rates.
Our debt may adversely affect our cash flow and may restrict our investment opportunities or limit our activities.
Goodwill and other intangible assets are subject to impairment.
Various international tax risks could adversely affect our earnings and cash flows.
The unpredictability and fluctuation of our quarterly results may adversely affect the trading price of our common stock.
Existing stockholders have significant influence over us.
Other companies may have difficulty acquiring us, even if doing so would benefit our stockholders, due to provisions under our corporate charter and bylaws, as well as Delaware law.
Full 10-K form ▸
|
|
related documents |
1109354--3/16/2009--BRUKER_CORP |
1109354--3/17/2008--BRUKER_CORP |
1109354--3/14/2006--BRUKER_BIOSCIENCES_CORP |
1109354--3/15/2007--BRUKER_BIOSCIENCES_CORP |
352363--2/23/2010--CLAIBORNE_LIZ_INC |
926844--5/29/2008--RENHUANG_PHARMACEUTICALS_INC |
926844--2/13/2007--RENHUANG_PHARMACEUTICALS_INC |
105319--3/3/2010--WEIGHT_WATCHERS_INTERNATIONAL_INC |
1110803--2/26/2010--ILLUMINA_INC |
790818--3/18/2010--X_RITE_INC |
1090872--12/21/2009--AGILENT_TECHNOLOGIES_INC |
738076--7/27/2009--3COM_CORP |
1090872--12/20/2010--AGILENT_TECHNOLOGIES_INC |
32198--3/31/2010--EMS_TECHNOLOGIES_INC |
1098880--3/30/2010--IntelGenx_Technologies_Corp. |
887730--5/25/2010--KEMET_CORP |
1003124--3/2/2006--PHARMACEUTICAL_PRODUCT_DEVELOPMENT_INC |
836429--10/12/2010--SYNERGETICS_USA_INC |
1065837--3/5/2010--SKECHERS_USA_INC |
67279--3/30/2010--MOCON_INC |
1173489--3/13/2009--CEVA__INC |
47217--12/15/2010--HEWLETT_PACKARD_CO |
1024732--2/25/2010--IGATE_CORP |
716314--5/25/2010--GRAHAM_CORP |
1001601--3/30/2010--MGT_CAPITAL_INVESTMENTS_INC |
876167--1/29/2010--PROGRESS_SOFTWARE_CORP_/MA |
1099800--2/26/2010--Edwards_Lifesciences_Corp |
868368--12/10/2010--ROCHESTER_MEDICAL_CORPORATION |
1032067--5/21/2010--MEADE_INSTRUMENTS_CORP |
1033905--2/25/2010--LUMINEX_CORP |
|